Læknablađiđ
-
The number of people with type 2 diabetes has increased in Iceland in the last few decades. We utilized the national database on prescribed medication from the Directorate of Health to estimate the prevalence and incidence of type 2 diabetes in Iceland and made prediction on the prevalence of type 2 diabetes in Iceland in 10 and 20 years. ⋯ Linear increase was seen in incidence and prevalence of people with type 2 diabetes in the years 2005-2018. Similar evolution was seen in USA from 1984. In order to counteract the increase of type 2 diabetes following the same path as has been seen in the USA, targeted measures are needed.
-
Electric scooters have become popular in Iceland. The aim of the current study was to gather data on the incidence, causes, and severity of injuries due to the use of electric scooters in the Reykjavik area during the summer of 2020. MATERIAL AND METHODS: Individuals presenting to the Emergency Department (ED) at Landspitali between June 1 and August 31 were asked about the location and cause of accident, use of protective equipment, and use of recreational drugs and alcohol. Diagnosis and treatment data was gathered from hospital records. RESULTS: During the study period, 149 individuals presented with electric scooter injuries, on average 1.6/day. ⋯ No children reported having been under the influence of alcohol or recreational drugs at the time of the accident, compared to 40% of adults who reported that they were intoxicated. Fractures were diagnosed in 38% of patients, 6% needed hospital admission, but no patient suffered serious injury. CONCLUSION: During the summer of 2020, one to two individuals were injured daily in the Reykjavík capital area while using electic scooters, but no serious injuries occurred. Preventive measures to decrease injury rate from the use of electric scooters should focus on infrastructure, encourage helmet use, and education on the risk of injury associated with operating electric scooters while intoxicated.
-
Observational Study
[The effect of fampridine on gait in people with Multiple sclerosis (MS)].
Fampridine is a drug for people with Multiple Sclerosis (MS). It is a broad-spectrum voltage-dependent potassium channel blocker that enhances synaptic transmission. The drug has been shown to be able to enhance conduction in demyelinated axons, thereby leading to improved gait in patients with MS. The purpose of this study was to examine the effect of fampridine on gait function in people with MS in the end of a 2 weeks trial drug period and to observe how many patients continued drug therapy. ⋯ Fampridine can have a positive effect on impaired gait function in people with MS and can be an important adjunct to treatment.